Stocksigma LogoStocksigma Logo

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

Tavexia Lifecare Limited has approved the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited via a cash subscription of

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 12 Oct 2026, 8:46 pm

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore Tavexia Lifecare Limited has approved the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited via a cash subscription of 2,09,97,180 fresh equity shares priced at ₹32 per share, totaling ₹67.19 Crore. The deal grants Tavexia immediate manufacturing and commercial infrastructure in MIDC Tarapur, Maharashtra. Alongside strategic expansion into APIs, finished formulations, CDMO/CRAMS, and nutraceuticals via an altered Object Clause, the company plans to fund the transaction through equity or convertible instruments.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements